Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants and instruments. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Alphatec Holdings Inc.

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on Alphatec Holdings on December 16 and set a price target of $25.00. According to...

Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity

Wells Fargo analyst Vik Chopra maintained a Buy rating on Alphatec Holdings today and set a price target of $20.00. Chopra covers the Healthcare se...

Current Quarter	$-0.09	Next Quarter	$-0.08
Current Year	$-0.89	Next Year	$-0.26
QoQ Growth	+11.1%	YoY Growth	+70.8%
3Y EPS CAGR	+0.0%	Target Price	$23.75
Consensus	Buy	Upside	+14.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATEC	$20.77	-1.10%	956.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATEC	$20.77	-1.1%	956.35K
3
4
5
6

ATEC

ATEC

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alphatec Holdings Inc. Data in Excel

Get Alphatec Holdings Inc. Data in Excel